Ascendis Pharma A/S (ASND)

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here.

On May 26, Michael Dehal, Senior Portfolio Manager at Dehal Investment Partners of Raymond James Ltd., appeared on BNN Bloomberg to discuss the outlook for the markets.

Operator: Good day, and thank you for standing by. Welcome to the First Quarter Ascendis Pharma Earnings Conference Call.

Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.

European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.

European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade.

Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years.

On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.

Operator: At this time, participants are in listen-only mode. Thank you for standing by, and welcome to the Ascendis Pharma A/S Fourth Quarter 2025 Earnings Conference Call.